1224436-76-3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 175696-50-1 tert-butyl [(2S,3S,4R)-1,3,4-trihydroxyoctadecan-2-yl]carbamate 
• 554-62-1 D-ribo-phytosphingosine 
• 1224436-75-2 (2S,3S,4R)-2-amino-1-((tert-butyldiphenylsilyl)oxy)octadecane-3,4-diol 

Downstream Products

• 1224436-77-4 C₅₃H₇₃NO₇Si 
• 1262283-53-3 C₃₉H₆₃NO₆SSi 
• 1262283-52-2 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-cyclic sulfate 
• 1262283-54-4 (4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-5-((R)-1-hydroxypentadecyl)oxazolidin-2-one 
• 1262283-55-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-5-hydroxy-6-tetradecyl-1,3-oxazinan-2-one 
• 1262283-61-3 (R)-1-((4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxooxazolidin-5-yl)pentadecyl methanesulfonate 
• 1262283-60-2 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl methanesulfonate 
• 1262283-63-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl trifluoromethanesulfonate 
• 1262283-59-9 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol dimethanesulfonate 
• 1226980-98-8 (S)-4-[(1S,2R)-2-(tert-butyldiphenylsilyloxy)-1-hydroxyhexadecyl]oxazolidin-2-one 
• 1226981-00-5 (S)-4-[(1S,2R)-1-(tert-butyldiphenylsilyloxy)-2-hydroxyhexadecyl]oxazolidin-2-one 

Relevant academic research and scientific papers

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.

Regioselective inversion of the hydroxyl group in d-ribo-phytosphingosine via a cyclic sulfate and bis-sulfonate intermediate

The selective synthesis of d-xylo-and d-lyxo-phytosphingosines from commercially available d-ribo-phytosphingosine is described. Thermolysis of the N-carbonyl protected cyclic sulfate led to an inversion of configuration of the proximal hydroxyl group to

Synthesis of a novel α-galactosyl ceramide haptenated-lipid antigen, a useful tool in demonstrating the involvement of i NKT cells in the production of antilipid antibodies

A new haptenated derivative of α-galactosyl ceramide (α-GalCer) has been synthesized to assist in the study of the mechanism of T cell help for the production of B cell antibodies. Our synthetic route provides access to an amine intermediate which can eas